Bietti crystalline corneoretinal dystrophy
MONDO:0008865Bietti's crystalline dystrophy (BCD) is a rare progressive autosomal recessive tapetoretinal degeneration disease, occurring in the third decade of life, characterized by small sparkling crystalline deposits in the posterior retina and corneal limbus in addition to sclerosis of the choroidal vessels and manifesting as nightblindness, decreased vision, paracentral scotoma, and, in the end stages of the disease, legal blindness.
Also known as: BCD, Bietti crystalline corneoretinal dystrophy, Bietti crystalline retinopathy, Bietti crystalline dystrophy, Bietti tapetoretinal Degeneration with marginal corneal dystrophy
34 clinical trials for this condition and its sub-types, 9 tagged with Bietti crystalline corneoretinal dystrophy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
One-Time gene injection aims to halt rare blindness
Disease control Not yet recruitingThis trial tests a single injection of a gene therapy called ZVS101e for people with Bietti crystalline dystrophy, a rare inherited eye disease that leads to progressive vision loss. The therapy uses a harmless virus to deliver a working copy of the CYP4V2 gene to cells in the ey…
Sponsor: Chigenovo Co., Ltd • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Gene therapy takes on rare eye disease in Second-Eye trial
Disease control Not yet recruitingThis study is for people with Bietti's crystalline dystrophy, a rare genetic eye disease that causes vision loss. They have already received the gene therapy VGR-R01 in one eye. Now, researchers want to test if giving the same treatment to the other eye is safe and can improve vi…
Phase 1/2 • Sponsor: Shanghai Vitalgen BioPharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC